This work was carried out to demonstrate the possibility of beneficial therapeutic effects of aspirin in sickle cell anaemia patients. Two groups of 50 patients each, with haemoglobin genotype SS were studied, one group receiving soluble aspirin daily for 6 weeks, while the other was used as a control. There was evidence of increase in oxygen affinity, in haemoglobin levels, and in the life span of RBC, probably due to acetylation of HbS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000207105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Barriers to Blood Donation: Donor Deferrals in a Saudi Hospital Setting.
Ann Clin Lab Sci
November 2024
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences-Al-Qurayyat, Jouf University, Saudi Arabia.
Objective: Blood donation plays a critical role in healthcare systems by supplying blood and blood products for surgeries, emergency care, and chronic disease management. In Saudi Arabia, the prevalence of genetic disorders, like sickle cell disease and thalassemia, further increase the need for a stable blood supply. However, high rates of donor deferrals remain a significant barrier to maintaining a reliable blood supply.
View Article and Find Full Text PDFFunctional Foods in Preventing Human Blood Platelet Hyperactivity-Mediated Diseases-An Updated Review.
Nutrients
October 2024
Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, 0313 Oslo, Norway.
Unlabelled: Backgrounds/Objectives: Abnormal platelet functions are associated with human morbidity and mortality. Platelets have emerged as critical regulators of numerous physiological and pathological processes beyond their established roles in hemostasis and thrombosis. Maintaining physiological platelet function is essential to hemostasis and preventing platelet-associated diseases such as cardiovascular disease, cancer metastasis, immune disorders, hypertension, diabetes, sickle cell disease, inflammatory bowel disease, sepsis, rheumatoid arthritis, myeloproliferative disease, and Alzheimer's disease.
View Article and Find Full Text PDFCurrent obstetric outcomes in Jamaican women with sickle hemoglobinopathy - a balance of risks for aspirin?
J Perinat Med
June 2024
Department of Obstetrics and Gynaecology, 233759 University Hospital of the West Indies, Mona, Jamaica.
Objectives: Sickle cell disease (SCD) occurs in 2.8 % of our Jamaican antenatal population with homozygous HbSS being most associated with adverse maternal and perinatal outcomes.
Methods: A retrospective comparative analysis of HbSS, HbSC and HbSβThal pregnancy outcomes at the University Hospital of the West Indies (UHWI) between January 2012 and December 2022 was conducted.
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel.
Blood Adv
February 2024
Department of Clinical Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom.
Data to guide evidence-based management of pregnant people with sickle cell disease (SCD) are limited. This international Delphi panel aimed to identify consensus among multidisciplinary experts for SCD management during pregnancy. The 2-round Delphi process used questionnaires exploring 7 topics (antenatal care, hydroxyurea use, transfusion, prevention of complications, treatment of complications, delivery and follow-up, and bottlenecks and knowledge gaps) developed by a steering committee.
View Article and Find Full Text PDFDrug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.
Int J Mol Sci
November 2023
Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus.
The design of clinical protocols and the selection of drugs with appropriate posology are critical parameters for therapeutic outcomes. Optimal therapeutic protocols could ideally be designed in all diseases including for millions of patients affected by excess iron deposition (EID) toxicity based on personalised medicine parameters, as well as many variations and limitations. EID is an adverse prognostic factor for all diseases and especially for millions of chronically red-blood-cell-transfused patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!